As 2024 Begins, US FDA’s Novel Agent Prospects Look A Lot Like 2023

 
• By Bridget Silverman
  
pills in mirror
FDA could see a reflection of its 2023 reviews in this year’s class. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers